A5113712976- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Polyomavirus and related diseases
- T-cell and B-cell Immunology
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Neutropenia and Cancer Infections
- Renal Transplantation Outcomes and Treatments
- Mesenchymal stem cell research
- Lymphoma Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Legume Nitrogen Fixing Symbiosis
- Viral-associated cancers and disorders
- Plant nutrient uptake and metabolism
- Childhood Cancer Survivors' Quality of Life
- Transplantation: Methods and Outcomes
- Platelet Disorders and Treatments
Agence de la Biomédecine
2006-2024
Institut Paoli-Calmettes
2011-2020
Inserm
1997-2018
Institut de Recherche pour le Développement
2018
Economic & Social Sciences, Health Systems & Medical Informatics
2018
Institut Pprime
1997-2017
Aix-Marseille Université
2014-2016
Centre Integre de Sante et de Services Sociaux de Laval
2015
Université de Montréal
2015
Société Française de Cardiologie
2010
Recently, the administration of high-dose cyclophosphamide (Cy) after T cell–replete haploidentical stem cell infusion has been reported to be feasible and effective. In original study, bone marrow (BM) was used as source cells. Here, we retrospectively analyzed use BM versus peripheral blood cells (PBSCs) in a cohort patients receiving transplantation nonmyeloablative conditioning regimen with postinfusion Cy. PBSC groups, incidence acute graft-versus-host disease (GVHD) 33% 25%,...
Background Recurrence of prior invasive fungal infection (relapse rate 30–50%) limits the success stem cell transplantation. Secondary prophylaxis could reduce disease burden and improve survival.Design Methods A prospective, open-label, multicenter trial was conducted evaluating voriconazole (4 mg/kg/12 h intravenously or 200 mg/12 orally) as secondary antifungal in allogeneic transplant recipients with previous proven probable infection. Voriconazole started 48 more after completion...
The Rhizobium meliloti nodH gene is involved in determining host range specificity. By comparison with the wild-type strain, NodH mutants exhibit a change That is, although lose ability to elicit root hair curling (Hac-), infection threads (Inf-), and nodule meristem formation (Nod-) on homologous alfalfa, they gain be Hac+ Inf+ Nod+ nonhomologous such as common vetch. Using deformation (Had) bioassays alfalfa vetch, we have demonstrated that sterile supernatant solutions of R. cultures,...
Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have a very poor prognosis. However, they may achieve long-term survival by undergoing allogeneic stem cell transplantation (SCT). The purpose of this study was to assess the outcome all adult patients DLBCL whose treatment included reduced-intensity conditioning (RIC) regimen for SCT and data were reported in French Society Marrow Transplantation Cellular Therapy registry. Sixty-eight (median age: 48 years)...
It has recently been shown that a T cell-replete allogeneic (allo) hematopoietic stem cell transplantation (HSCT) from haploidentical donor (haplo-ID) could be valid treatment for hematological malignancies. However, little data exist concerning older populations. We provided to 31 patients over the age of 55 years haplo-ID and compared their outcomes with same ages who underwent matched related (MRD) or an unrelated (UD). All 3 groups were comparable, except conditioning. Patients in group...
We retrospectively analyzed outcomes of a CD34(+)-selected stem cell boost (SCB) without prior conditioning in 32 patients (male/22; median age 54 years; range, 20 to 69) with poor graft function, defined as neutrophils ≤1.5 x 10(9)/L, and/or platelets ≤30 hemoglobin ≤8.5 g/dL). The interval between transplantation and SCB was 5 months (range, 2 228). number CD34(+) CD3(+) cells were 3.4 10(6)/kg (.96 8.30) 9 10(3)/kg body weight 70), respectively. Hematological improvement observed 81%...
The optimal intensity of reduced-intensity conditioning (RIC) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains uncertain.In this centrally randomized phase 2 study, the authors compared different strategies RIC. In total, 139 patients (median age, 54 years; range, 21-65 years) with hematologic malignancies underwent allo-HSCT from a human leukocyte antigen-identical sibling after combining fludarabine either busulfan and rabbit antithymocyte-globulin (BU-rATG) (n...